New treatment options against gram-negative organisms

Bassetti, Matteo; Ginocchio, Francesca; Mikulska, Małgorzata

doi:10.1186/cc9997

Cited by 104 publications

(56 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another remedy is to conduct extensive preclinical development and new clinical trials for the repurposing drug candidates in order to find new optimal dosing and formulation. Approved anti‐infective agents identified from the repurposing screen may be used immediately to treat patients with severe infections for which they were not developed initially (Bassetti et al , 2011). Conversely, non‐anti‐infective drugs such as antihypertensive and antihistamine agents, once found from drug repurposing screens, typically do need new clinical trials to demonstrate their safety and efficacy for the treatment of infections (He et al , 2015).…”

Section: Assays For Drug Repurposing Screensmentioning

confidence: 99%

Drug repurposing screens and synergistic drug‐combinations for infectious diseases

Zheng

Sun

Simeonov

2017

British J Pharmacology

213

200

View full text Add to dashboard Cite

Infectious diseases account for nearly one fifth of the worldwide death toll every year. The continuous increase of drug‐resistant pathogens is a big challenge for treatment of infectious diseases. In addition, outbreaks of infections and new pathogens are potential threats to public health. Lack of effective treatments for drug‐resistant bacteria and recent outbreaks of Ebola and Zika viral infections have become a global public health concern. The number of newly approved antibiotics has decreased significantly in the last two decades compared with previous decades. In parallel with this, is an increase in the number of drug‐resistant bacteria. For these threats and challenges to be countered, new strategies and technology platforms are critically needed. Drug repurposing has emerged as an alternative approach for rapid identification of effective therapeutics to treat the infectious diseases. For treatment of severe infections, synergistic drug combinations using approved drugs identified from drug repurposing screens is a useful option which may overcome the problem of weak activity of individual drugs. Collaborative efforts including government, academic researchers and private drug industry can facilitate the translational research to produce more effective new therapeutic agents such as narrow spectrum antibiotics against drug‐resistant bacteria for these global challenges.Linked ArticlesThis article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc

show abstract

Section: Assays For Drug Repurposing Screensmentioning

confidence: 99%

Drug repurposing screens and synergistic drug‐combinations for infectious diseases

Zheng

Sun

Simeonov

2017

British J Pharmacology

213

200

View full text Add to dashboard Cite

show abstract

“…This situation is so dire that the World Health Organization has recognized multidrug resistant (MDR) bacteria as one of the top three threats to human health (Bassetti et al, 2011). Novel approaches to combating infections caused by these bacteria are sorely needed.…”

Section: Introductionmentioning

confidence: 99%

Combined efficacy of thymol and silver nanoparticles against Staphylococcus aureus

Abdelhamid¹,

El‐Hosseiny²

2017

Afr. J. Microbiol. Res.

View full text Add to dashboard Cite

Due to the looming spread of resistance to classical antimicrobial agents, innovative therapeutic methods are in dire need to combat the onslaught of resistant bacterial pathogens. This study examines the antimicrobial efficacy of a phytochemical and a metallic nanoparticle against the top Gram positive resistant pathogen. The potential synergy of these two agents was also evaluated. The antibacterial activity of thymol and silver nanoparticles were tested individually using disc diffusion technique. The extent of synergy of their combination was evaluated using the checkerboard assay. Twenty clinical isolates of Staphylococcus aureus characterized as methicillin resistant or methicillin sensitive Staphylococcus aureus were utilized and the extent of synergism was calculated from fractional inhibitory concentration indices. Thymol exhibited an antistaphylococcal activity regardless of whether the isolates were phenotypically resistant or sensitive to methicillin. Combining thymol with silver nanoparticles resulted in at least additive or synergistic effect for all the examined strains and methicillin resistant strains were inhibited in the combinatorial assays to a greater extent comparative to when silver nanoparticles or thymol were used singly.

show abstract

“…The World Health Organization recently recognized antimicrobial resistance as one of the three major human health problems. (1) In the last decade, gram-negative bacilli were highlighted as generators of HAIs. From this time onwards, epidemiologic monitoring processes started being addressed as a relevant strategy toward the creation of prevention measures.…”

Section: Introductionmentioning

confidence: 99%

Prevalência de bactérias gram-negativas em portadores de HIV internados em serviço especializado

et al. 2015

View full text Add to dashboard Cite

Objective: To identify the prevalence of gram-positive bacteria in patients with HIV and who are hospitalized in specialized services. Methods: The present cross-sectional study approached 365 patients admitted in two specialized units of a teaching hospital located in the countryside of the state of São Paulo. The population was composed of 220 subjects. Sociodemographic and clinical data were obtained by means of individual interviews and medical record analysis. Saliva and nasal secretion were collected in the first 24 hours of the hospitalization process. Results: The prevalence of gram-negative bacteria in patients with HIV reached 14.5%, regardless of the site of their isolation. Pseudomonas aeruginosa was the most frequently isolated microorganism, followed by Klebsiella pneumoniae. Conclusion: The identification level of gram-negative bacteria was higher in the saliva (11.8%) than in the nasal secretion (3.6%), thus indicating that the collection of samples in more than one site may favor the identification of colonized and/or infected individuals. ResumoObjetivo: Identificar a prevalência de bactérias gram-negativas em portadores de HIV internados em serviço especializado. Métodos: Trata-se de um estudo de corte transversal, foram abordados 365 indivíduos internados em duas unidades especializadas, de um hospital escola do interior paulista, sendo a população composta por 220 sujeitos. Os dados sociodemográficos e clínicos e foram obtidos por meio de entrevista individual e consulta aos prontuários. Coletaram-se também amostras de saliva e secreção nasal nas primeiras 24 horas de internação. Resultados: A prevalência de bactérias gram-negativas em portadores de HIV foi de 14,5 % independente do sítio onde foi isolado. Pseudomonas aeruginosa foi o microorganismo mais frequentemente isolado, seguida por Klebsiella pneumoniae. Conclusão: A identificação de bactérias gram-negativas foi maior na saliva (11,8%) que na secreção nasal (3,6%), indicando que coletar amostras de mais de um sítio pode favorecer a identificação de indivíduos colonizados e ou infectados.

show abstract

New treatment options against gram-negative organisms

Cited by 104 publications

References 47 publications

Drug repurposing screens and synergistic drug‐combinations for infectious diseases

Drug repurposing screens and synergistic drug‐combinations for infectious diseases

Combined efficacy of thymol and silver nanoparticles against Staphylococcus aureus

Prevalência de bactérias gram-negativas em portadores de HIV internados em serviço especializado

Contact Info

Product

Resources

About